Insight into Sweet's syndrome and associated-malignancy: A review of the current literature

Raza,Shahzad; Kirkland,Robert  S.; Patel,Anand  A.; Shortridge,James  R.; Freter,Carl

doi:10.3892/ijo.2013.1874

Insight into Sweet's syndrome and associated-malignancy: A review of the current literature

Authors:
- Shahzad Raza
- Robert S. Kirkland
- Anand A. Patel
- James R. Shortridge
- Carl Freter
View Affiliations

Affiliations: Division of Hematology and Oncology, Ellis Fischel Cancer Center, Columbia, MO 65203, USA, University of Missouri School of Medicine, Columbia, MO 65203, USA
Published online on: March 28, 2013 https://doi.org/10.3892/ijo.2013.1874
Pages: 1516-1522

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sweet's syndrome (acute febrile neutrophilic dermatosis) is an infrequent skin disease characterized by sudden onset of fever, leucocytosis and erythematous plaques or nodules infiltrated by neutrophils. There are three main clinical settings in which Sweet's syndrome has been described: classical or idiopathic Sweet's syndrome, malignancy-associated Sweet's syndrome and drug-induced Sweet's syndrome. Classical Sweet's is often preceded by an upper respiratory tract infection and may be associated with inflammatory bowel disease and pregnancy. Approximately 21% of patients have an associated malignancy, most commonly hematological disease. The syndrome may occur as a paraneoplastic accompaniment to established cancer or may be a first sign of malignancy or its recurrence. The incidence is said to be increasing in recent years due to the frequent use of growth factors in cancer patients. Several anticancer agents including all-trans-retinoic acid proteosome inhibitors, hypomethylating agents, tyrosine kinase inhibitors and lenalidomide are potential harbingers of Sweet's syndrome. Unfortunately, little is known about the pathophysiology of Sweet's syndrome and there are no established guidelines for treatment of malignancy-associated Sweet's syndrome. Systemic corticosteroids are the mainstay of treatment. Sweet's syndrome caused by anticancer agents sometimes involves withdrawal or temporary discontinuation of anticancer agents, use of systemic corticosteroids and/or rechallenge with either with the same anticancer agents or different agents. This report provides insights into the pathophysiology, clinical presentation, diagnostic work, differential diagnosis and management of malignancy-associated Sweet's syndrome published in reported cases.

View Figures

View References

1.	Sweet RD: An acute febrile neutrophilic dermatosis. Br J Dermatol. 76:349–356. 1964. View Article : Google Scholar : PubMed/NCBI
2.	Cohen PR: Sweet’s syndrome: a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2:342007.
3.	Su WPD and Liu H-NH: Diagnostic criteria for Sweet’s syndrome. Cutis. 37:167–174. 1986.
4.	von den Driesch P: Sweet’s syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 31:535–556. 1994.
5.	Cohen PR and Kurzrock R: Sweet’s syndrome and cancer. Clin Dermatol. 11:149–157. 1993.
6.	Paydas S: Sweet’s syndrome: a revisit for hematologists and oncologists. Crit Rev Oncol Hematol. Oct 6–2012.(Epub ahead of print). View Article : Google Scholar
7.	Cohen PR, Talpaz M and Kurzrock R: Malignancy-associated Sweet’s syndrome: review of the world literature. J Clin Oncol. 6:1887–1897. 1988.
8.	Haverstock C, Libecco JF, Sadeghi P, et al: Tender erythematous plaques in a woman with acute myelogenous leukemia. Arch Dermatol. 142:235–240. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Disel U, Paydas S, Yavuz S, et al: Bilateral ear Sweet’s syndrome in a case with relapse acute myeloblastic leukemia. Leuk Res. 30:3642006.
10.	Cohen PR: Cutaneous paraneoplastic syndromes. Am Fam Physician. 50:1273–1282. 1994.PubMed/NCBI
11.	Kurzrock R and Cohen PR: Mucocutaneous paraneoplastic manifestations of hematologic malignancies. Am J Med. 99:207–216. 1995. View Article : Google Scholar : PubMed/NCBI
12.	Kurzrock R and Cohen PR: Cutaneous paraneoplastic syndromes in solid tumors. Am J Med. 99:662–671. 1995. View Article : Google Scholar : PubMed/NCBI
13.	Cohen PR: Cutaneous manifestations of internal malignancy. Section V, Dermatology. Current Practice of Medicine. Callen JP and Bone RC: Current Medicine, Philadelphia, PA, Inc; 2(V): pp. 19.1–19.3. 1996
14.	Cohen PR and Kurzrock R: Paraneoplastic syndromes of the skin. Current Diagnosis 9. Conn RB, Borer WZ and Snyder JW: W.B. Saunders Co; Philadelphia, PA: pp. 1199–1206. 1997
15.	Morgan KW, Callen JP and Kentucky L: Sweet’s syndrome in acute myelogenous leukemia presenting as periorbital cellulitis with an infiltrate of leukemic cells. J Am Acad Dermatol. 45:590–595. 2001.
16.	Caughman W, Stern R and Haynes H: Neutrophilic dermatosis of myeloproliferative disorders: atypical forms of pyoderma gangrenosum and Sweet’s syndrome associated with myeloproliferative disorders. J Am Acad Dermatol. 9:751–758. 1983.PubMed/NCBI
17.	Bamelis M, Boyden B, Sente F, et al: Sweet’s syndrome and acute myelogenous leukemia in a patient who presented with a sudden massive swelling of the tongue. Dermatology. 190:335–337. 1995.
18.	García-Río I, Pérez-Gala S, Aragüés M, et al: Sweet’s syndrome on the area of postmastectomy lymphoedema. J Eur Acad Dermatol Venereol. 20:401–405. 2006.
19.	Matta M and Kurban AK: Sweet’s syndrome: systemic association. Cutis. 12:561–565. 1973.
20.	Elsner P, Hartmann AA and Lechner W: Sweet’s syndrome associated with Yersinia enterocolitica infection. Dermatologica. 173:85–89. 1986.
21.	Arun B, Berberian B, Azumi N, et al: Sweet’s syndrome during treatment with all-trans retinoic acid in a patient with acute promyelocytic leukemia. Leuk Lymphoma. 31:613–615. 1998.
22.	Paydas S, Sahin B and Zorludemir S: Sweet’s syndrome accompanying leukaemia: seven cases and review of the literature. Leuk Res. 24:83–86. 2000.
23.	Arbetter KR, Hubbard KW, Markovic SN, et al: Case of granulocytic colony-stimulating factor-induced Sweet’s syndrome. Am J Hematol. 61:126–129. 1999.PubMed/NCBI
24.	Giasuddin AS, El-Orfi AH, Ziu MM and El-Barnawi NY: Sweet’s syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines. J Am Acad Dermatol. 39:940–943. 1998.
25.	Tuerlinckx D, Bodart E, Despontin K, et al: Sweet’s syndrome with arthritis in a 8-month-old boy. J Rheumatol. 26:440–442. 1999.
26.	Kawakami T, Ohashi S, Kawa Y, et al: Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of Sweet syndrome and patients with active Behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol. 140:570–574. 2004. View Article : Google Scholar
27.	Oiso N, Watanabe K and Kawada A: Granulocyte colony-stimulating factor-induced Sweet syndrome in a healthy donor. Br J Haematol. 135:1482006. View Article : Google Scholar : PubMed/NCBI
28.	Shinojima Y, Toma Y and Terui T: Sweet syndrome associated with intrahepatic cholangiocarcinoma producing granulocyte colony-stimulating factor. Br J Haematol. 154:1103–1104. 2006.
29.	Requena L, Kutzner H, Plamedo G, et al: Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes. Arch Dermatol. 141:834–842. 2005. View Article : Google Scholar : PubMed/NCBI
30.	Walker DC and Cohen PR: Trimethoprim-sulfamethoxazole associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet’s syndrome. J Am Acad Dermatol. 34:918–923. 1996.PubMed/NCBI
31.	Cohen PR and Kurzrock R: Sweet’s syndrome. A neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol. 18:265–282. 2000.
32.	Bidyasar S, Montoya M, Suleman K, et al: Sweet syndrome associated with granulocyte colony-stimulating factor. J Clin Oncol. 26:4355–4356. 2008. View Article : Google Scholar : PubMed/NCBI
33.	Llamas-Velasco M, García-Martín P, Sánchez-Pérez J, et al: Sweet’s syndrome with subcutaneous involvement associated with pegfilgrastim treatment: first reported case. J Cutan Pathol. 40:46–49. 2013.
34.	Van Regenmortel N, Van de Voorde K, De Raeve H, et al: Bortezomib-induced Sweet’s syndrome. Haematologica. 90:ECR432005.
35.	Tanguy-Schmidt A, Avenel-Audran M, Croué A, et al: Bortezomib-induced acute neutrophilic dermatosis. Ann Dermatol Venereol. 136:443–446. 2009. View Article : Google Scholar
36.	Alencar C, Abramowitz M, Parekh S, et al: Atypical presentations of Sweet’s syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors. Am J Hematol. 84:688–689. 2009.
37.	Trickett HB, Cumpston A and Craig M: Azacitidine-associated Sweet’s syndrome. Am J Health Syst Pharm. 69:869–871. 2012.PubMed/NCBI
38.	Deininger MW, O’Brien SG, Ford JM, et al: Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 21:1637–1647. 2003. View Article : Google Scholar : PubMed/NCBI
39.	Liu D, Seiter K, Mathews T, et al: Sweet’s syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate. Leuk Res. 28(Suppl 1): S61–S63. 2004.
40.	Ayirookuzhi SJ, Ma L, Ramshesh P, et al: Imatinib-induced Sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol. 141:368–370. 2005. View Article : Google Scholar : PubMed/NCBI
41.	Hoverson AR, Davis MD, Weenig RH, et al: Neutrophilic dermatosis (Sweet syndrome) of the hands associated with lenalidomide. Arch Dermatol. 142:1070–1071. 2006. View Article : Google Scholar : PubMed/NCBI
42.	Thieu KP, Rosenbach M, Xu X, et al: Neutrophilic dermatosis complicating lenalidomide therapy. J Am Acad Dermatol. 61:709–710. 2009. View Article : Google Scholar
43.	Tageja N, Giorgadze T and Zonder J: Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia. Intern Med J. 41:286–288. 2011. View Article : Google Scholar
44.	Aue G, Njuguna N, Tian X, et al: Lenalidomide induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica. 94:1266–1273. 2009. View Article : Google Scholar
45.	Yan ZS, Li DP, Jiang EL, et al: Development of Sweet syndrome in an acute promyelocyte leukemia patient during treatment with all-trans retinoic acid - case report and literature review. Zhonghua Xue Ye Xue Za Zhi. 28:462–465. 2007.PubMed/NCBI
46.	Dubois C, Schlageter MH, de Gentile A, et al: Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia. Leukemia. 8:1750–1757. 1994.PubMed/NCBI
47.	Bielsa S, Baradad M, Marti RM, et al: Sweet’s syndrome with bullous lesions. Actas Dermosifiliogr. 96:315–316. 2005.
48.	Shugarman IL, Schmit JM, Sbicca JA, et al: Easily missed extracutaenous manifestation of malignancy associated Sweet’s syndrome: systemic inflammatory response syndrome. J Clin Oncol. 29:e702–705. 2011.PubMed/NCBI
49.	Cohen PR: Neutrophilic dermatoses: a review of current treatment options. Am J Clin Dermatol. 10:301–312. 2009. View Article : Google Scholar : PubMed/NCBI
50.	Cohen PR and Kurzrock R: Sweet’s syndrome: a review of current treatment options. Am J Clin Dermatol. 3:117–131. 2002.
51.	Spillman DH, Carabajal MG, Errecaborde MS, et al: Acute febrile neutrophilic dermatosis (Sweet’s syndrome). In: Book of Abstracts. 18th World Congress of Dermatology. Dermatology Progress and Perspectives; June 12–18; New York City. abs. 147. 1992
52.	Cohen PR, Holder WR, Tucker SB, Kono S and Kurzrock R: Sweet syndrome in patients with solid tumors. Cancer. 72:2723–2731. 1993. View Article : Google Scholar : PubMed/NCBI
53.	Horio T, Imamura S, Danno K, et al: Treatment of acute neutrophilic dermatosis (Sweet’s syndrome) with potassium iodide. Dermatologica. 160:341–347. 1980.
54.	Burrall B: Sweet’s syndrome (acute febrile neutrophilic dermatosis). Dermatol Online J. 5:81999.
55.	Bourke JF, Keohane S, Long CC, et al: Sweet’s syndrome and malignancy in the U.K. Br J Dermatol. 137:609–613. 1997.
56.	Maillard H, Leclech C, Peria P, et al: Colchicine for Sweet’s syndrome. A study of 20 cases. Br J Dermatol. 140:565–566. 1999.
57.	von den Driesch P, Steffan C, Zobe A, et al: Sweet’s syndrome-therapy with cyclosporin. Clin Exp Dermatol. 19:274–277. 1994.
58.	Jeanfils S, Joly P, Young P, et al: Indomethacin treatment of eighteen patients with Sweet’s syndrome. J Am Acad Dermatol. 36:436–439. 1997.PubMed/NCBI